|
**Overview**: Activated Partial Thromboplastin Time Mixing Studies Panel**Introduction**: The Activated Partial Thromboplastin Time Mixing Studies Panel is a diagnostic tool designed to assess coagulation factor deficiencies using plasma samples. In India, prolonged APTT due to factor deficiencies (VIII, IX, XI, XII) or inhibitors (lupus anticoagulant, acquired hemophilia) causes bleeding diathesis or thrombosis, with hemophilia A/B underdiagnosed in rural/low-SES males (~1 in 5,000-10,000). High morbidity from delayed diagnosis leading to joint bleeds, hemarthrosis, or life-threatening hemorrhage. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs immunoassay for APTT patient, normal plasma mix, PT, INR, and factor deficiency assessment over 1-2 days with high accuracy, valuable for differentiating factor deficiency from inhibitor. This diagnostic falls under coagulation screening and targets patients with prolonged APTT, bleeding history, or pre-surgery, addressing accurate detection to guide factor replacement or bypassing agents. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise coagulopathy evaluation and reducing bleeding complications. Its plasma-based approach ensures reliable mixing study.**Other Names**: APTT Mixing Pnl.**FDA Status**: FDA approved, CLIA certified for hematology, compliant with 2025 standards.**Historical Milestone**: APTT mixing study standard; in India, used in hemophilia clinics.**Purpose**: The test assesses 6 parameters including APTT patient to guide coagulation assessment, differentiate deficiency/inhibitor, inform replacement.**Test Parameters**: 1. APTT Patient, 2. APTT Normal Plasma, 3. APTT Mix, 4. PT, 5. INR, 6. Factor Deficiency.**Pretest Condition**: No fasting required; patients should have prolonged APTT or bleeding.**Specimen**: 3 mL plasma in NaCit tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve coagulation factors, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on bleeding history, family hemophilia.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected coagulopathy including hemorrhage, benefits of screening, and minimal discomfort from sampling.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique and interpret mixing correction within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or heparin contamination can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Correction with normal plasma indicates factor deficiency; no correction suggests inhibitor, necessitating specialist input.**Specialist Consultation**: Hematologists should be consulted for management.**Additional Supporting Tests**: Factor assays, Bethesda titer for confirmation.**Test Limitations**: Affected by anticoagulants; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Coagulation Studies India 2023. |
